Madhushri M

In this present work Erythromycin stearate nanosuspension has been formulated. Since Erythromycin stearate is insoluble in water, it has been formulated as nanosuspension to improve bioavailability of the drug. The formulation was carried out using High Pressure Homogenization method using different variables like drug-surfactants ratio, stirring speed and rotation time, to optimize the final formulation while keeping the quantities of active ingredient constant. An optimized final formulation was prepared by using drug, poloxamer 188 and tween20 in 1:2:2 ratios with stirring speed of 25000 rpm for 25 minutes using High Pressure Homogenizer (Polytron PT 1600E) followed by lyophilisation. The optimized final formulation was subjected to in-vitro parameters such as compatibility, drug content, particle size analysis, zeta-potential, SEM, in-vitro release profile. All the in vitro evaluation parameters complied the limits. Stability studies were also conducted as per ICH guidelines and from the result it may be concluded that the optimized formulation is stable. Finally, it is concluded that the drug is compatible and stable with the excipients, hence Erythromycin stearate can be formulated as nanosuspension by this method. Key words: Erythromycin stearate, Poloxamer 188, Nanosuspension, Zeta potential, DSC, SEM.    

The purpose of this research was to develop a desired topical formulation containing clotrimazole for treatment of fungal infections like eczema, itching, pruritis etc. Topical formulation enriched with SLN of clotrimazole were prepared. The solid lipid nanoparticulate dispersion of clotrimazole was prepared by hot homogenization technique using polymers like Carbopol 934, mannitol and PEG 6000. The nanoparticulate dispersion was evaluated for various parameters such as physical evaluations, particle size, diffusion studies, DSC, SEM, stability studies. The solid lipid nanoparticulate dispersion showed mean particle size less than 1000 nm. Differential scanning Calorimetry studies revealed no drug excipient incompatibility. Diffusion studies release profile of clotrimazole from nanoparticulate dispersion showed prolonged drug release. And all other evaluations were found to be complied the limits. Thus it can be concluded that formulation of SLN containing clotrimazole can be successfully formulated to localize the drug in the skin for to treat topical fungal infections.

SLN’s are colloidal carriers developed in the 1990s as an alternative system to the existing traditional carriers (emulsions, liposomes, and polymeric nanoparticles)1. Nanoparticles made from solid lipids are attracting major attention as novel colloidal drug carrier for various applications as they have been proposed as an alternative particulate carrier system. The SLNS are submicron colloidal carriers (50-1000 nm) which are composed of physiological lipid, dispersed in water or in an aqueous surfactant solution2.SLNs are particles consisting of a matrix made from solid lipids. In aqueous dispersion they are stabilised by surfactants or polymers. They consist of a solid matrix protecting incorporated active substances against chemical degradation and providing high flexibility to modify release profiles. The SLN combine the advantages (e.g. physical stability, protection of incorporated labile drugs from degradation, controlled release, excellent tolerability, and scalability to large-scale preparations, excellent biocompatibility) of other traditional colloidal systems3.